nab-paclitaxel + gemcitabine Clinical Trials

5 actively recruiting trials across 1 location

No change since May 2026

Pipeline

Phase 2: 2Phase 3: 2Phase 1/2: 1

Top Sponsors

Jiangsu HengRui Medicine Co., Ltd.2
Fudan University1
Dartmouth-Hitchcock Medical Center1
Chinese PLA General Hospital1

Indications

Cancer5
First-line Treatment of Metastatic Pancreatic Cancer1
First-line Treatment of Advanced Pancreatic Cancer1
Pancreas Adenocarcinoma1
Pancreatic Cancer Metastatic1

Other4 trials

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Phase 3

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Phase 3

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Phase 1/2

Lebanon, New Hampshire1 trial

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Dartmouth-Hitchcock Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.